Haemonetics has secured approval from the US Food and Drug Administration (FDA) for its NexSys PCS plasma collection system enhancements.
The advancements include a new plasma collection bowl with a patented design for optimised performance and new Express Plus Technology that has been developed to minimise procedure time.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
They will enable Haemonetics to take an average procedure time of 33 to 38 minutes with the standard FDA nomogram, thereby providing customers with improved plasma centre efficiency and reduced cost of collection.
The bi-directionally linked NexSys PCS with NexLynk DMS donor management software has already been offering an average 16-minute-less donor door-to-door time, with the majority portion of this improvement happening before and after the procedure.
Furthermore, NexSys PCS when combined with Persona Technology is capable of offering an average of +9% to 12% additional plasma yield by customising each collection to the individual characteristics of the donor.
Haemonetics expects to release NexSys PCS with the new bowl and Express Plus Technology in the market over the next few months.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataHaemonetics Global Plasma and Blood Center president Roy Galvin said: “Haemonetics sets the standard in global plasma collection solutions that meet collectors’ most critical needs.
“With our redesigned bowl and new Express Plus Technology for faster procedure times and enhanced plasma centre efficiency, we continue to advance our innovation to lead the industry in reducing cost per litre for collectors and ensuring the best experience for their donors.”
